This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e64. Learning Objective-Upon completion of this activity, successful learners will be able to choose critically the exams that should be performed to diagnose autoimmune pancreatitis; recognize, diagnose, and describe possible other organ involvement in patients with IgG4-related autoimmune pancreatitis; and select the most appropriate test in the evaluation of suspected exocrine pancreatic insufficiency.
A utoimmune pancreatitis (AIP) is a peculiar form of pancreatitis with specific clinical, radiologic, serologic, and histologic features. [1] [2] [3] Although the vast majority of AIP patients 4 initially respond to glucocorticoids, a significant proportion of patients relapse once steroid therapy is discontinued or reduced. The clinical course of the disease can be more severe in patients who relapse, with accelerated progression toward chronic changes, with development of biliary strictures, pancreatic insufficiency, and extrapancreatic manifestations. 5, 6 Therefore, prevention of relapse remains a major issue in the long-term management of AIP.
Several prospective and retrospective studies of steroidbased regimens for treatment of AIP have been published, 4, [7] [8] [9] [10] with relapse rates ranging broadly from 9.8% 11 to 62%. 12 The results of these studies are inconclusive or conflicting because of the relatively small sample size, short period of follow-up evaluation, and differences in baseline patient characteristics, diagnostic criteria, steroid dose (first course), maintenance protocol, definition of relapse, and re-treatment regimen. Importantly, the rate of relapse is known to be much higher in type 1 AIP, which is more common in Asia, in men, and in the seventh decade of life. Type 1 AIP is characterized by the presence of IgG4 and often involves other organs (60% of cases). Type 2 AIP occurs more frequently in Western countries, equally in younger men and women, is IgG4 negative, and is associated with inflammatory bowel disease. 13 When this distinction is not possible, AIP is defined as not otherwise specified.
In 2014, the Japanese consensus panel on AIP 14 concluded that maintenance steroid therapy (MST) with low-dose steroid should last for up to 3 years, with cessation in cases with radiologic and serologic improvement. In most Western countries, including the United States, 15 steroid treatment is tapered over a period of 12 to 16 weeks, after an induction period of 2 to 4 weeks. In 2017, the last consensus on treatment of AIP concluded that "maintenance therapy with low-dose glucocorticoids or steroid-sparing agents may be useful in some patients with type 1 AIP" 10 after successful induction of remission. Therefore, questions persist regarding the modality of steroid tapering, MST and its duration, and the use of immunomodulating agents for maintenance.
To increase statistical power and to reduce uncertainty, we propose a systematic review and meta-analysis of the available studies. The aims of this meta-analysis were as follows: (1) to analyze the variability in AIP relapse rates by looking at the heterogeneity among the studies as a means of interpreting this; (2) to assess the efficacy of MST in reducing relapse rate; and, finally, (3) to identify risk factors for AIP relapse.
Methods

Literature Search and Study Selection
This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (Supplementary Table 1) . 16 A systematic search of MEDLINE, EMBASE, and SCOPUS databases was performed including the following terms: "autoimmune pancreatitis," "relapse," "steroid therapy," and "maintenance." The search included reports published until July 2018.
To identify additional studies, the computer search was supplemented with manual searches of the reference lists of all review articles and primary studies retrieved. When the results of a single study were reported in more than one publication, only the most recent and complete data were included in the meta-analysis. Moreover, we performed a search for abstracts presented at main relevant pancreatic conference proceedings (United European Gastroenterology week, Digestive Disease Week, and European Pancreatic Club) during the past 4 years. Abstracts that had been published subsequently as a full-text study were excluded if a full-text study already was included in the meta-analysis.
Studies were included in the meta-analysis if they met the following criteria: (1) patients had a diagnosis of AIP according to International Consensus Diagnostic Criteria 7 for AIP, Mayo Clinic's HiSORT criteria, 17 Japanese Pancreas Society guidelines, 18 or Asian diagnostic criteria 19 ; (2) steroid therapy was used for induction at an initial dose of at least 0.5 mg/kg/day or at least 20 What You Need to Know Background Autoimmune pancreatitis (AIP) is a form of pancreatitis that can have multiple sequelae, such as exocrine and endocrine pancreatic insufficiency or extrapancreatic complications (eg, biliary stricture). Almost 100% of patients respond successfully to glucocorticoids, but data on relapse remain equivocal. Moreover, there is debate on how long maintenance steroid therapy (MST) should last
Findings
This meta-analysis of aggregate data from 31 studies shows that there is significant heterogeneity among relapse rates, which ranged from 9.8% to 59.2%. The pooled relapse rate was 32% (95% CI, 28%-35%) during a median follow-up period of 40.9 months. Subgroup analysis showed that the relapse rate was significantly lower for long-term MST than for shortterm MST (27% vs 38%, respectively; P ¼ .01). The benefit of long-term MST was confirmed by multivariate meta-regression.
Implications for patient care
This meta-analysis, which included more than 3000 patients with AIP, shows the efficacy of long-term MST in the prevention of disease relapse. In particular, patients with AIP type 1 could benefit from this type of regimen. The results of this meta-analysis are subject to several limitations, such as differences in design, sample size, baseline severity of illness, and maintenance regimens. Further randomized controlled trials are needed to determine the optimal duration and modality (steroid vs immunosuppressant) of maintenance therapy. mg/day; (3) steroid therapy was used for maintenance of remission; and (4) the proportion of patients with relapse was reported.
Studies were excluded if the patient cohorts included in the studies were overlapping, (in this case, only the more recent study was included), or if the follow-up time was shorter than 6 months.
Literature Review
Study-level variables included the last name of the first author, publication year, region where the study was conducted, study design, number of patients treated with steroids, number of centers (single vs multiple), length of follow-up evaluation, length of MST, definition of relapse, and study quality. Because of the lack of a worldwide accepted definition of relapse, we classified the studies according to their definition of AIP relapse into 3 categories: undefined (studies in which a clear definition of relapse was not reported), radiologic, or clinical and radiologic.
Studies were categorized based on the length of MST as short vs long term (shorter vs longer than 1 year).
Patient-level variables included age, sex, type of AIP (1 or 2), median IgG4 level at baseline, and the number of patients with diffuse enlargement of the pancreas, as shown by imaging. Each study was evaluated and classified by 3 independent investigators (M.T., C.C., and B.M). We performed a systematic review evaluating risk factors for AIP relapse in all the studies included in the meta-analysis.
Discrepancies among reviewers were not frequent (interobserver variation, <10%) and were resolved by discussion.
Assessment of Study Quality
All studies were assessed for study quality according to a checklist based on a modified version of the Newcastle-Ottawa quality assessment scale, 20 with discrepancies resolved by consensus (Supplementary Table 2 ). Studies were graded using the following parameters: (1) representativeness of the exposed cohort, (2) ascertainment of exposure, (3) demonstration that outcome of interest was not present at the start of the study, (4) assessment of outcome, (5) sufficient period of follow-up evaluation, and (6) adequacy of follow-up evaluation. Each parameter was given a numeric score from 0 to 2. Studies with scores of 9 or greater were classified as high quality, and scores lower than 9 were classified as low quality. In abstract, it was not possible to assess methodologic quality.
Statistical Analysis
The crude relapse rate was extracted as an outcome measure. Pooled estimates were obtained using a random-effects model with the generic inverse variance method. The method of moments estimator, proposed by DerSimonian and Laird, was used to assess betweenstudy variance. 21, 22 Heterogeneity was assessed with the Pearson chi-square test and the I 2 statistic. We considered a priori subgroups based on study-level (publication year, region where the study was conducted, study design, number of centers, length of follow-up evaluation, length of maintenance, definition of relapse, and study quality) and patient-level variables (age, sex, AIP type, IgG4 levels, and diffuse pancreatic enlargement on imaging). Univariate and multivariate logistic meta-regression analysis was used to examine associations between patient-or study-level covariates and relapse rate. Variables with a P value less than .1 in univariate meta-regression were included in multivariate meta-regression. For all other analyses, a P value less than .05 was considered statistically significant. The amount of heterogeneity in the outcome explained by risk factors was evaluated with the R 2 index. The Egger regression test was performed to evaluate the asymmetry of the Begg funnel plot and potential publication bias. We used the nonparametric approach reported by Combescure et al 23 to assess the pooled relapse probability over time. R Core Team (2018): A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria) was used to obtain all analyses and graphics.
Results
Literature Search
Our primary search identified 414 titles. After removal of duplicate articles, we identified 176 studies. We excluded 104 articles because they were not consistent with our aim. Finally, 72 studies (62 full-text articles and 10 abstracts) were included in a qualitative synthesis and full-text was reviewed to establish eligibility for quantitative analysis. After review of the studies, 31 full-text articles 6,9,11,12,24-50 and 5 abstracts [51] [52] [53] [54] [55] (1 randomized clinical trial, 21 retrospective studies, and 14 prospective studies) fulfilled the inclusion criteria and were selected for meta-analysis ( Figure 1 ). and 12 were conducted in Western countries. 5, 12, 28, 30, 31, 35, 38, 43, 46, 51, 54, 55 Two were multinational studies. 6, 40 Twenty-three studies were conducted at single centers. [24] [25] [26] [27] [28] [29] [30] 33, 35, [37] [38] [39] 42, [49] [50] [51] [52] [53] [54] [55] Thirteen studies were multicentric. 6, 9, 11, 12, 31, 34, 36, 40, 41, [45] [46] [47] [48] In 8 studies 12, 24, [32] [33] [34] 36, 44, 50 relapse was defined radiologically, whereas in 17 studies 9, [27] [28] [29] [30] [31] 35, [39] [40] [41] [42] [45] [46] [47] [48] [49] 54 it was defined clinically and radiologically. Relapse was not clearly defined in 11 studies (including 4 abstracts). 6, 11, 25, 26, 37, 38, 43, [51] [52] [53] 55 In 16 studies 9, 11, [24] [25] [26] 29, 32, 37, 39, 41, 44, 45, 47, 48, 50, 55 MST lasted more than 1 year (long-term maintenance). In 13 studies 12, 27, 28, 30, 31, 33, 35, 36, 38, 42, 43, 46, 49 MST was shorter than 1 year (short-term maintenance). The randomized controlled trial (RCT) 34 and the large multinational multicentric study 40 included were split into 2 subgroups according to length of MST. The length of MST was not defined clearly in 1 full-text article 6 and in 4 abstracts. [51] [52] [53] [54] The median length of follow-up evaluation differed among studies, ranging from 6 38 44 with a median of 383 mg/dL. The 
Study Characteristics
Relapse Rate
The pooled estimate for the overall AIP relapse rate among patients treated with steroids was 33% (95% CI, 30%-37%; I 2 , 79%; P < .01) (Figure 2A ), ranging from 9.8% 11 to 62%. 31 Relapse curves were extracted from the studies in which Kaplan-Meier curves were available. 24, 26, 29, 31, 32, 34, 47, 48 Summary relapse curves are shown in Figure 3 . One-year, 2-year, and 3-year actuarial relapse rates were available in 8 studies; the 4-year actuarial relapse rate was available in 5 studies. The pooled actuarial relapse rate was 20% (95% CI, 7%-32%) at 1 year, 37% (95% CI, 14%-54%) at 2 years, 48% (95% CI, 22%-66%) at 3 years, and 53% (95% CI, 27%-69%) at 4 years.
Predictors of Relapse
To identify potential risk factors for AIP relapse, 31 different variables were evaluated among 17 studies, as shown in Table 2 . Variables found to be significant risk factors for AIP relapse by univariate analysis in at least 3 studies were as follows: pretreatment IgG4 value, persistently increased IgG4 value, other organ involvement, and induction and maintenance with steroid treatment. Jaundice was the most common significant risk factor for AIP relapse by multivariate analysis.
Subgroup Analysis
The pooled relapse rate was lower in studies with MST treatment for longer than 1 year, compared with studies in which MST lasted less than 1 year (27% vs 39%; P ¼ .01) ( Figure 2B ). The relapse rate was lower in studies in which relapse was defined as clinical and radiologic and in studies with undefined relapse criteria than in studies in which relapse was defined radiologically (32% and 32% vs 37%, respectively); however, this difference was not statistically significant (P ¼ .69) (Supplementary Figure 1A) . A sensitivity analysis after exclusion of 11 studies that did not clearly define AIP relapse showed a similar relapse rate (34%; 95% CI, 29%-38%), in comparison to the overall effect (Supplementary Figure 2) . The relapse rate was significantly higher in studies classified as high quality, compared with studies classified as low quality (39% vs 29%, respectively; P ¼ .03) (Supplementary Figure 1B) . The relapse rate also was significantly higher in studies conducted in Western countries, compared with studies conducted in Asia and multinational studies (42% vs 30% and 27%; P < .01) (Supplementary Figure 1C) . A significant difference also was observed between studies published before vs after 2014 (26% vs 39%; P < .01). The relapse rate was similar between prospective and retrospective studies (38% vs 29%, respectively; P ¼ .08) (Supplementary Figure 1D) , between unicentric and multicentric studies (34% vs 33%; P ¼ .76), and between studies with a median follow-up evaluation shorter vs longer than 2 years (26% vs 35%; P ¼ .10) (Supplementary Figure 3A-C) . Regarding patient-level variables, there was no significant difference in relapse rate with respect to age, sex, IgG4 values, or the presence of diffuse pancreatic enlargement as shown by imaging. When data were analyzed according to AIP type, the relapse rate was significantly higher in patients with type 1 AIP than in patients with type 2 AIP (37.5% vs 15.9%; P < .001; odds ratio, 3.18; 95% CI, 1.86-5.75) (Supplementary Figure 4) . The AIP relapse rate was higher in studies in which International Consensus Diagnostic Criteria were used for diagnosis than in studies that used different diagnostic criteria (37% vs 30%; P ¼ .08) (Supplementary Figure 3D) .
Meta-Regression
Univariate logistic meta-regression analysis was performed to identify potential sources of heterogeneity among studies. Among the variables assessed, long-term MST (P ¼ .007) was associated significantly with a lower relapse rate, whereas high study quality (P ¼ .004) and year of publication after 2014 (P < .001) were associated significantly with a higher relapse rate. The length of MST, study quality, and year of publication accounted for 26.9%, 16.1%, and 31.2%, respectively, of overall heterogeneity. Multivariate logistic meta-regression showed that long-term MST was associated significantly with an 11.6% decrease in relapse rate (95% CI, 4.0%-19.2%; P ¼ .003), whereas high study quality was associated with a 9.8% increase in relapse rate (95% CI, 1.8%-17.9%; P ¼ .016) ( Table 3 ). IgG4 median values were available in only 10 studies and for this reason this variable was not evaluated by multivariate meta-regression. After excluding studies in which diagnostic criteria for relapse were undefined, year of publication (P ¼ .013), length of follow-up evaluation (P ¼ .02), length of MST (P ¼ .08), study quality (P ¼ .057), and male sex (P ¼ .069) were associated with relapse by univariate logistic meta-regression analysis. After adjustment for year of publication and study quality, long-term MST was associated with an 11.8% decrease in relapse rate (P ¼ .008), while length of follow-up evaluation longer than 2 years was associated significantly with a higher relapse rate (P ¼ .02), by multivariate meta-regression (Supplementary Table 5 ).
Publication Bias
The results of the funnel publication bias plot for relapse rate (Supplementary Figure 5) and the Egger test for publication bias showed that the risk of having missed or overlooked studies was not significant (P ¼ .06).
Quality Assessment
A quality assessment of included studies is provided in Supplementary Table 3 . Five of 30 studies had cohorts that were appropriately representative. Exposure ascertainment, defined by using international diagnostic criteria 7 or HiSORT, 17 was achieved by 68% of studies. Seventeen studies 9, [27] [28] [29] [30] [31] 35, [39] [40] [41] [42] [45] [46] [47] [48] [49] 54 ascertained AIP relapse using clinical and radiologic criteria, whereas 8 studies 12, 24, [32] [33] [34] 36, 44, 50 did not report a clear definition of relapse.
Discussion
Evidence regarding the risk of relapse after induction of remission with steroids in patients with AIP is sparse and heterogeneous. A consistent estimation of relapse rate among patients with AIP treated with steroid is essential for assessing the efficacy of new treatment strategies, for calculating sample size, and for interpreting the results of additional RCTs. This systematic review and meta-analysis of aggregate data from 36 studies shows that the clinical course after steroid-induced remission remains highly variable. We found a pooled relapse rate of 33%, although this point estimate must be interpreted in the context of clinical and methodologic limitations of the published data. A significant reduction in the relapse rate was observed in long-term MST studies. The benefit of long-term MST was confirmed by multivariate meta-regression. As expected, we found a high degree of heterogeneity among studies. The inconsistency in relapse rate among studies is not surprising if one considers differences in design, power, potential biases in the selection of patients with different demographic and clinical characteristics, and, finally, different definitions of relapse and maintenance protocol. Therefore, we performed further analyses to identify groups of studies with consistent rates of relapse. Nevertheless, our subgroup and meta-regression analyses were unable to fully explain the observed heterogeneity. Although the studies included in the metaanalysis used different criteria for AIP relapse, subgroup and meta-regression analyses after exclusion of studies that did not clearly define relapse had similar results. Therefore, a standardized and worldwide accepted definition of AIP relapse is urgently needed. Taking all this in consideration, because of the limited quality of AIP relapse definition, our results seem to be informative but still not conclusive regarding the role of MST. After stratification according to study location, our analysis showed a significant difference in relapse rate between Asian and Western countries (30% vs 42%, respectively). This discrepancy could be related to different approaches in terms of maintenance therapy or to differences in proportions of type 1 and type 2 AIP between Western and Asian countries. Indeed, type 1 AIP is more common in Asian countries, and MST is used commonly in such cases. One of the current issues in the field of AIP is whether MST may be useful to prevent relapse and, if so, how long MST should be maintained. It is not clear whether all patients with AIP should receive MST, or whether MST should be administered only to a subgroup of patients who clearly stand to benefit. In 2017, the last International Consensus meeting on AIP treatment 10 concluded that maintenance therapy with low-dose glucocorticoids or steroid-sparing agents may be useful in some patients with type 1 AIP. We added further evidence that the relapse rate after MST significantly differs between type 1 and type 2 AIP (37% vs 16%, respectively). However, data on relapse rate according to AIP type are scanty. Identification of potential risk factors for AIP relapse can be useful to select patients who are more likely to benefit from maintenance therapy. According to the last International Consensus for treatment of AIP, 10 we found that IgG4 levels, jaundice, and other organ involvement were the most relevant risk factors associated with AIP relapse.
Our meta-analysis showed considerable variation among studies in dose and length of MST, suggesting that standardized regimens are urgently needed. Pannala and Chari 15 suggested tapering steroids over a period of 12 to 16 weeks, after an induction period of 2 to 4 weeks. By contrast, a large multicentric retrospective study 9 showed that the relapse rate was significantly lower in patients treated with low-dose (2.5-10 mg/day) long-term MST, compared with those who stopped maintenance therapy. Based on these results, Asian experts 14 recommend a maintenance duration of at least 6 months. In 2017, a RCT by Masamune et al 34 showed that the 3-year relapse rate differed significantly between long-term and short-term MST (23.3% vs 57.9%, respectively). This is the only RCT available on the topic, and it had several limitations, 56 such as small sample size and an imbalance in the number of patients treated with long-vs short-term MST. As part of this meta-analysis, we performed multivariate metaregression to show that the relapse rate was significantly lower (27%) in studies with long-term MST, compared with studies with short-term MST (39%). However, this finding may be biased by the lack of follow-up evaluation of patients with long-term MST after steroid discontinuation.
The pooled actuarial curves of AIP relapse from 8 studies showed that approximately half of all patients experienced relapse after 4 years of follow-up evaluation. Although obtained from a small number of studies, this result supports the clinical rationale to prolong MST and highlights the importance of designing future RCTs with an adequate sample size, stratification by AIP type, and extended length of follow-up evaluation. Recent studies have reported a role for immunosuppressant drugs [57] [58] [59] in treatment of the first relapse. RCTs comparing longterm MST vs immunosuppressants (mainly azathioprine) could be useful to substantiate the benefit of immunosuppressant therapy in decreasing the rate of relapse.
The results of this meta-analysis are subject to several limitations. Differences in design, in sample size, in baseline severity of illness, in AIP relapse definition, and in maintenance regimens may limit the accuracy of this quantitative analysis. We attempted to control for these differences by including patient-and study-level covariates. However, there were likely other potentially important confounders for which we did not control and that might have affected the results. Lack of data on the distribution between patients with type 1 vs type 2 AIP, on the pattern of presentation (pancreatic vs extrapancreatic), and on factors associated with the likelihood of relapse in AIP may have affected the accuracy of the results. Furthermore, the results only describe variation between studies, rather than between patients, because they reflect group averages rather than individual data. More detailed comparisons could be achieved with metaanalyses of individual patient data. As with all metaanalyses, this study also has the potential limitation of the generalizability of results to new populations and settings. Meta-analyses are likely to have poor external validity when the included studies all use the same limited patient population or are all conducted in a single setting. Because AIP patients are a heterogeneous population, we decided to include studies with different designs and those that included patients treated with different first steroid courses and re-treated with different maintenance regimens. We believe that this approach may have improved the generalizability of our data to results observed in real clinical practice. A methodologic issue of the current study is the potential limitation of the generalizability of its results to different populations and settings, given that the benefit of longterm MST was observed particularly in Asian patients, limiting the broad application of the results to a Western population. With our extensive computer search for studies, we are confident that no important published studies were overlooked. Publication bias was not substantial and was considered unlikely to change the magnitude of our pooled estimates.
The available evidence is sufficient to conclude the following: (1) the risk of relapse after induction of remission with steroids in patients with AIP remains high during long-term follow-up evaluation, particularly in patients with type 1 AIP; (2) MST significantly reduces the risk of AIP relapse; and (3) the benefit of long-term MST appears to be observed more consistently in Asian populations. Further large-scale, multicenter RCTs may prove useful to substantiate the benefit of long-term MST and to compare steroid maintenance with steroidsparing immunosuppressive drug therapy. 
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